Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial
Clinical Gastroenterology and Hepatology · 2026-06 · 24 (6) · 1611-1620
DOI: 10.1016/j.cgh.2025.09.009 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-06. Verfasst von Rong Fan und 16 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Multi-organ Injury Prevention and Treatment, Key Laboratory of Infectious Diseases Research in South China, Ministry of Educa…. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic, Antiviral Agents, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
BACKGROUND & AIMS: Nucleos(t)ide analogue (NAs) discontinuation promotes hepatitis B surface antigen (HBsAg) clearance among European patients with chronic hepatitis B virus (HBV) infection. The efficacy and safety of a novel HBV biomarker-guided NAs withdrawal strategy among Asian patients was evaluated in this multicenter randomized controlled trial. METHODS: NAs-experienced patients achieving HBsAg
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Multi-organ Injury Prevention and Treatment, Key Laboratory of Infectious Diseases Research in South China, Ministry of Education, Guangdong Provincial Key Laboratory for Prevention and Control o…
- Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hepatology, Shenzhen Third People's Hospital, National Clinical Research Center for Infectious Disease, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Sh…
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Peking University Hepatology Institute, Peking University People's Hospital, Beijing, China.
- Department of Hepatology, The First Hospital of Jilin University, Jilin University, Changchun, China.
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Fan, R., Deng, R., Xie, Q., Wang, F., Liang, X., Ma, H., Rao, H., Gao, Y., Zhong, C., Guo, Q., Shen, S., Xu, Y., Lu, X., Gao, H., Bai, H., Dou, X., & Sun, J. (2026). Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 24(6), 1611-1620. https://doi.org/10.1016/j.cgh.2025.09.009
Vancouver
Fan R, Deng R, Xie Q, Wang F, Liang X, Ma H, et al. Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 2026;24(6):1611-1620. doi:10.1016/j.cgh.2025.09.009
BibTeX
@article{Fan2026,
author = {Fan, Rong and Deng, Rui and Xie, Qing and Wang, Fang and Liang, Xieer and Ma, Hong and Rao, Huiying and Gao, Yanhang and Zhong, Chunxiu and Guo, Qing and Shen, Sheng and Xu, Ya and Lu, Xingyu and Gao, Hongbo and Bai, Honglian and Dou, Xiaoguang and Sun, Jian},
title = {Novel HBV Biomarkers-Guided NAs Withdrawal Strategy Promotes HBsAg Clearance in Asian CHB Patients: A Randomized Controlled Trial},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {6},
pages = {1611--1620},
doi = {10.1016/j.cgh.2025.09.009}
}
EUVIMED